atovaquone + proguanil hydrochloride: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
atovaquone + proguanil hydrochloride: clinical details
Prescribing considerations
- Base malaria prevention on destination-specific risk, parasite resistance, traveller characteristics and mosquito-bite avoidance.
- Confirm body weight and select a formulation licensed for the intended indication and weight range.
- Persistent vomiting or diarrhoea may reduce absorption. For acute malaria, consider alternative therapy or closely monitor clinical and parasitological response.
- Treatment failure or infection after prophylaxis should prompt use of a different blood schizonticide and consideration of resistance.
- Do not use as sole treatment for P. vivax or P. ovale when eradication of dormant liver forms is required.
Contraindications and cautions
- Hypersensitivity to either active ingredient or a formulation excipient.
- Severe renal impairment when used for malaria prophylaxis.
- For treatment in severe renal impairment, an alternative should be used whenever possible.
Monitoring
- Review renal function where impairment is known or suspected.
- Monitor parasitaemia and clinical condition when treating malaria complicated by vomiting or diarrhoea.
- Monitor INR where a coumarin anticoagulant is continued.
- Monitor treatment response closely with concurrent tetracycline or following suspected prophylaxis or treatment failure.
Clinical pharmacology
The fixed combination acts against hepatic and blood schizonts of P. falciparum. Atovaquone inhibits the parasite mitochondrial cytochrome bc1 complex; proguanil contributes through cycloguanil-mediated dihydrofolate reductase inhibition and potentiation of mitochondrial effects. Food substantially increases atovaquone absorption.
Formulation and product differences
- Adult and paediatric products are film-coated tablets with different active-ingredient content and distinct licensed body-weight ranges.
- Selected paediatric tablets may be crushed and mixed with food or a milky drink immediately before administration when swallowing is difficult.
- Adult and paediatric tablets are not automatically interchangeable; verify the exact product and indication.
atovaquone + proguanil hydrochloride preparations and strengths
Tablet
Route: Oral
Strengths: 62.5 mg + 25 mg, 250 mg + 100 mg
atovaquone + proguanil hydrochloride interactions
Check all prescribed, over-the-counter and travel medicines before use.
Rifampicin or rifabutin
Substantially lowers atovaquone exposure, so concurrent use is not recommended.
Metoclopramide
Can substantially reduce atovaquone concentrations; another antiemetic should usually be considered.
Efavirenz or boosted HIV protease inhibitors
May markedly lower atovaquone exposure and should be avoided with the combination where possible.
Warfarin and other coumarin anticoagulants
Proguanil may increase anticoagulant effects, requiring closer INR assessment when treatment starts or stops.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.